Preoperative molecular testing in thyroid nodules with Bethesda VI cytology: Clinical experience and review of the literature.
Ontology highlight
ABSTRACT: Risk assessment is critical to determine the timing of elective surgeries and preserve valuable resources in time of pandemic. This study was undertaken to better understand the potential value of molecular testing to risk-stratify thyroid nodules with malignant cytology (Bethesda VI). Systematic review of the literature contributed 21 studies representing 2036 preoperative specimens. The BRAF p.V600E substitution was detected in 46% to 90% of cases with a pooled positivity rate of 70% (95% confidence intervals: 64%-76%). None of the studies used comprehensive oncogene panels. Retrospective analysis of 531 clinical specimens evaluated with the next-generation sequencing ThyGeNEXT Thyroid Oncogene Panel identified a total of 436 gene alterations. BRAF mutation rate was 64% in specimens test
SUBMITTER: Labourier E
PROVIDER: S-EPMC7983887 | biostudies-literature | 2021 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA